STOCK TITAN

PhaseBio Pharmaceuticals to Present at the William Blair Biotech Focus Conference 2021 on July 15

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

PhaseBio Pharmaceuticals (Nasdaq: PHAS) announced that CEO Jonathan P. Mow will participate in a fireside chat at the William Blair Biotech Focus Conference 2021 on July 15, 2021, from 1:00 to 1:45 PM EDT. The event will be available via live webcast on the company's website, with a replay accessible for 90 days post-event. PhaseBio specializes in therapies for cardiopulmonary diseases and is advancing its pipeline, including bentracimab and pemziviptadil.

Positive
  • None.
Negative
  • None.

PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, today announced that Chief Executive Officer Jonathan P. Mow will participate in a fireside chat during the upcoming William Blair Biotech Focus Conference 2021 taking place virtually on Thursday, July 15, 2021 at 1:00 pm – 1:45 pm EDT.

The event will be available via live webcast from the “Events and Presentations” page of the “Investors” section of the company’s website at www.phasebio.com. The webcast replay will be available for 90 days after the conclusion of the live presentation.

About PhaseBio

PhaseBio Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiovascular and cardiopulmonary diseases. The company’s pipeline includes: bentracimab (PB2452), a novel reversal agent for the antiplatelet therapy ticagrelor; pemziviptadil (PB1046), a once-weekly VIP receptor agonist for the treatment of pulmonary arterial hypertension; and PB6440, an oral agent for the treatment of resistant hypertension. PhaseBio’s proprietary elastin-like polypeptide technology platform enables the development of therapies with potential for less-frequent dosing and improved pharmacokinetics, including pemziviptadil, and drives both internal and partnership drug-development opportunities.

PhaseBio is located in Malvern, PA, and San Diego, CA. For more information, please visit www.phasebio.com, and follow us on Twitter @PhaseBio and LinkedIn.

FAQ

When is the PhaseBio Pharmaceuticals fireside chat?

The fireside chat is scheduled for July 15, 2021, from 1:00 to 1:45 PM EDT.

Where can I watch the PhaseBio Pharmaceuticals webcast?

The webcast will be available on PhaseBio's website under the 'Events and Presentations' section.

What is the focus of PhaseBio Pharmaceuticals?

PhaseBio Pharmaceuticals focuses on developing novel therapies for cardiopulmonary diseases.

What are some products in PhaseBio's pipeline?

PhaseBio's pipeline includes bentracimab (PB2452) and pemziviptadil (PB1046).

How long will the PhaseBio webcast replay be available?

The webcast replay will be available for 90 days after the live presentation.

PhaseBio Pharmaceuticals Inc

NASDAQ:PHAS

PHAS Rankings

PHAS Latest News

PHAS Stock Data

Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Malvern